Search results for " Middle"

showing 10 items of 1097 documents

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis

2003

Familial hypobetalipoproteinemia (FHBL) subjects may develop fatty liver. Liver fat was assessed in 21 FHBL with six different apolipoprotein B (apoB) truncations (apoB-4 to apoB-89) and 14 controls by magnetic resonance spectroscopy (MRS). Liver fat percentages were 16.7 +/- 11.5 and 3.3 +/- 2.9 (mean +/- SD) (P = 0.001). Liver fat percentage was positively correlated with body mass index, waist circumference, and areas under the insulin curves of 2 h glucose tolerance tests, suggesting that obesity may affect the severity of liver fat accumulation in both groups. Despite 5-fold differences in liver fat percentage, mean values for obesity and insulin indexes were similar. Thus, for similar…

MaleVery low-density lipoproteinSettore MED/09 - Medicina InternaApolipoprotein Bmedicine.medical_treatmentPalmitic AcidLipoproteins VLDLSeverity of Illness IndexTriglyceridevery low density lipoprotein assemblyBiochemistryBody Mass IndexMagnetic resonence spectroscopy; Nonalcoholic fatty liver; Nonesterified fatty acids; Very low density lipoprotein assembly; Adult; Body Mass Index; Dietary Fats; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypobetalipoproteinemias; Insulin Resistance; Lipoproteins VLDL; Liver Diseases; Male; Middle Aged; Obesity; Palmitic Acids; Severity of Illness Index; Triglycerides; EndocrinologyHypobetalipoproteinemiaschemistry.chemical_compoundEndocrinologyDietary FatGlucose tolerance testmedicine.diagnostic_testbiologyChemistryLiver DiseasesLiver DiseaseFatty liverMiddle AgedFemalemagnetic resonence spectroscopyHumanAdultmedicine.medical_specialtyPalmitic Acidsnonesterified fatty acidsQD415-436Internal medicinemedicinenonalcoholic fatty liverHumansObesityTriglyceridesTriglycerideInsulinNonesterified fatty acidCell BiologyGlucose Tolerance Testmedicine.diseaseDietary FatsFatty LiverEndocrinologybiology.proteinHypobetalipoproteinemiaInsulin ResistanceSteatosisHypobetalipoproteinemiaJournal of Lipid Research
researchProduct

Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection

2014

Item does not contain fulltext Cervical artery dissection (CeAD), a mural hematoma in a carotid or vertebral artery, is a major cause of ischemic stroke in young adults although relatively uncommon in the general population (incidence of 2.6/100,000 per year). Minor cervical traumas, infection, migraine and hypertension are putative risk factors, and inverse associations with obesity and hypercholesterolemia are described. No confirmed genetic susceptibility factors have been identified using candidate gene approaches. We performed genome-wide association studies (GWAS) in 1,393 CeAD cases and 14,416 controls. The rs9349379[G] allele (PHACTR1) was associated with lower CeAD risk (odds ratio…

Male[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyMyocardial InfarctionGenome-wide association studyCarotid Artery Internal DissectionGastroenterologyepidemiology [Carotid Artery Internal Dissection]Brain Ischemia0302 clinical medicineMigraine DisorderOdds RatioFinlandVertebral Artery Dissection0303 health scienceseducation.field_of_studyepidemiology [Hypercholesterolemia]MESH: Middle AgedMESH: Polymorphism Single NucleotidePhactr-1 protein humanMESH: Brain IschemiaMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionHumanmedicine.medical_specialtyMigraine DisordersHypercholesterolemiaMESH: Vertebral Artery DissectionLower riskgenetics [Brain Ischemia]ArticleFollow-Up StudieMESH: Carotid Artery Internal Dissection03 medical and health sciencesGeneticSDG 3 - Good Health and Well-beinggenetics [Carotid Artery Internal Dissection]GeneticsGenetic predispositionepidemiology [Brain Ischemia]Humansepidemiology [Vertebral Artery Dissection]PolymorphismeducationAllelesMESH: Humansgenetics [Vertebral Artery Dissection]MESH: AdultOdds ratioMicrofilament Proteinmedicine.diseaseAdult; Brain Ischemia; Carotid Artery Internal Dissection; Female; Finland; Follow-Up Studies; Genetic Pleiotropy; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hypercholesterolemia; Hypertension; Male; Microfilament Proteins; Middle Aged; Migraine Disorders; Myocardial Infarction; Obesity; Odds Ratio; Risk Factors; Vertebral Artery Dissection; Alleles; Polymorphism Single NucleotideMESH: Genome-Wide Association StudyCarotid ArteryMESH: Female030217 neurology & neurosurgeryepidemiology [Finland]Cervical ArteryVertebral artery dissectionepidemiology [Hypertension]MESH: HypertensionRisk FactorsMESH: Risk FactorsMESH: ObesityStrokeAlleleGeneticsDissectionMESH: FinlandMicrofilament ProteinsMESH: Genetic Predisposition to DiseaseMESH: HypercholesterolemiaGenetic PleiotropySingle NucleotideMiddle AgedMESH: Migraine DisordersDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]epidemiology [Myocardial Infarction][INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV]HypertensionFemale[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingAdultPopulationMESH: Genetic Pleiotropyphysiology [Microfilament Proteins]BiologyPolymorphism Single NucleotideMESH: Microfilament ProteinsInternal medicineddc:570medicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingGenetic Predisposition to DiseaseObesity030304 developmental biologyepidemiology [Obesity]Risk FactorMESH: Alleles[INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV]InternalMESH: Odds RatioMESH: Maleepidemiology [Migraine Disorders]genetics [Microfilament Proteins]Follow-Up StudiesGenome-Wide Association Study
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2013

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyMESH: Intention to Treat AnalysisMESH: Venous Thromboembolism0302 clinical medicineMESH: Aged 80 and overRecurrence030212 general & internal medicineMESH: WarfarinAged 80 and overMESH: AgedMESH: Middle AgedMESH: RiskHazard ratioAtrial fibrillationVenous ThromboembolismGeneral MedicineMESH: Follow-Up StudiesMiddle AgedIntention to Treat Analysis3. Good healthPulmonary embolismMESH: International Normalized RatioMESH: beta-AlanineMESH: Young AdultAnesthesiaFemaleMESH: Hemorrhagemedicine.drugAdultRiskAdolescentHemorrhageLower riskPlaceboDabigatranDabigatran Venous ThromboembolismYoung Adult03 medical and health sciencesmedicineHumansInternational Normalized RatioAgedMESH: AdolescentIntention-to-treat analysisMESH: Humansbusiness.industryWarfarinMESH: Adultmedicine.diseaseMESH: MaleMESH: Recurrencebeta-AlanineBenzimidazolesWarfarinbusinessMESH: BenzimidazolesVenous thromboembolismMESH: FemaleFollow-Up Studies
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

2005

International audience; Background: Resource utilisation and direct costs associated with glaucoma progression in Europe are unknown. As population progressively ages, the economic impact of the disease will increase. Methods: From a total of 1655 consecutive cases, the records of 194 patients were selected and stratified by disease severity. Record selection was based on diagnoses of primary open angle glaucoma, glaucoma suspect, ocular hypertension, or normal tension glaucoma; 5 years minimum follow up were required. Glaucoma severity was assessed using a six stage glaucoma staging system based on static threshold visual field parameters. Resource utilisation data were abstracted from the…

Maleage distributionOrganes des sensgenetic structuresOffice VisitsOcular hypertensionGlaucomaDiseaseintraocular hypertensionSeverity of Illness IndexIndirect costs0302 clinical medicineambulatory careNormal tension glaucomamiddle agedopen angle glaucoma80 and overMedicine030212 general & internal medicinepathophysiologystatistical significanceAged 80 and overeducation.field_of_studyadultdisease coursearticlehealth care costclinical trialHealth Care Costshealth care planningSensory Systems3. Good healthEuropeagedfemalepriority journalstatisticsHealth Resourcesdisease severityadult; aged; article; disease course; disease severity; Europe; female; follow up; general practitioner; glaucoma; health care cost; health care utilization; human; intraocular hypertension; major clinical study; male; medical record; open angle glaucoma; priority journal; statistical significance; visual field; age distribution; ambulatory care; clinical trial; drug cost; economics; health care planning; hospitalization; middle aged; multicenter study; pathophysiology; sex ratio; statistics; utilization review; Adult; Age Distribution; Aged; Aged 80 and over; Drug Costs; Europe; Female; Follow-Up Studies; Glaucoma; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Office Visits; Severity of Illness Index; Sex Distribution; Visual Fieldshospitalizationvisual fieldWorld Viewsmedicine.medical_specialtyOpen angle glaucomadrug costPopulationSensory OrgansMédecine humaine et pathologiemedical recordDrug Costs03 medical and health sciencesCellular and Molecular Neurosciencehealth care utilizationSeverity of illnessfollow upHumanshumanSex Distribution[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organseducationutilization reviewSettore MED/30 - Malattie Apparato Visivobusiness.industryGlaucomaeconomicssex ratiomedicine.diseasemajor clinical studyeye diseasesOphthalmologymulticenter studygeneral practitionerEmergency medicine030221 ophthalmology & optometryOptometryHuman health and pathologyVisual Fieldsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

2014

Importance There is an urgent need to identify reliable biomarkers of amyotrophic lateral sclerosis (ALS) progression for clinical practice and pharmacological trials. Objectives To correlate several hematological markers evaluated at diagnosis with ALS outcome in a population-based series of patients (discovery cohort) and replicate the findings in an independent validation cohort from an ALS tertiary center. Design, Setting, and Participants The discovery cohort included 712 patients with ALS from the Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis from January 1, 2007, to December 31, 2011. The validation cohort comprised 122 patients with ALS at different stages of…

MaleanalysisGastroenterologyCohort Studieschemistry.chemical_compoundAdult Aged Aged; 80 and over Amyotrophic Lateral Sclerosis; blood/mortality/pathology Biological Markers; blood Cohort Studies Creatinine; blood Disease Progression Female Humans Italy Lymphocyte Count Male Middle Aged Outcome Assessment (Health Care) Predictive Value of Tests Prognosis Sensitivity and Specificity Serum Albumin; analysisblood/mortality/pathologyOutcome Assessment Health Care80 and overAged 80 and overeducation.field_of_studybiologymedicine.diagnostic_testHazard ratioMiddle AgedPrognosisItalyErythrocyte sedimentation rateCreatinineCohortDisease ProgressionSettore MED/26 - NeurologiaBiological MarkersFemaleCohort studyAdultmedicine.medical_specialtyPopulationSerum albuminSensitivity and SpecificityOutcome Assessment (Health Care)bloodPredictive Value of TestsInternal medicinemedicineHumansLymphocyte CounteducationSerum AlbuminAgedCreatininebusiness.industryAmyotrophic Lateral SclerosisAlbuminchemistryImmunologybiology.proteinNeurology (clinical)ALSbusinessBiomarkersJAMA neurology
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct